Bulla R, Bossi F, Tedesco F
Front Immunol. 2012; 3:55.
PMID: 22566936
PMC: 3341982.
DOI: 10.3389/fimmu.2012.00055.
Lee W, Ko Y, Kim D, Lee B, Park J
Korean J Intern Med. 2000; 15(2):117-21.
PMID: 10992723
PMC: 4531756.
DOI: 10.3904/kjim.2000.15.2.117.
Baumgarth N, Herman O, Jager G, Brown L, Herzenberg L
Proc Natl Acad Sci U S A. 1999; 96(5):2250-5.
PMID: 10051627
PMC: 26769.
DOI: 10.1073/pnas.96.5.2250.
Molina H, Holers V, Li B, Fung Y, Mariathasan S, Goellner J
Proc Natl Acad Sci U S A. 1996; 93(8):3357-61.
PMID: 8622941
PMC: 39612.
DOI: 10.1073/pnas.93.8.3357.
Dayer J, Demczuk S
Springer Semin Immunopathol. 1984; 7(4):387-413.
PMID: 6395411
DOI: 10.1007/BF00201968.
Structure and function of the anaphylatoxins.
Hugli T
Springer Semin Immunopathol. 1984; 7(2-3):193-219.
PMID: 6387982
DOI: 10.1007/BF01893020.
The chemistry and biology of complement receptors.
Schreiber R
Springer Semin Immunopathol. 1984; 7(2-3):221-49.
PMID: 6238434
DOI: 10.1007/BF01893021.
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.
Fingeroth J, Weis J, Tedder T, Strominger J, Biro P, Fearon D
Proc Natl Acad Sci U S A. 1984; 81(14):4510-4.
PMID: 6087328
PMC: 345620.
DOI: 10.1073/pnas.81.14.4510.
Isolation of complement-fragment-iC3b-binding proteins by affinity chromatography. The identification of p150,95 as an iC3b-binding protein.
Micklem K, Sim R
Biochem J. 1985; 231(1):233-6.
PMID: 4062888
PMC: 1152732.
DOI: 10.1042/bj2310233.
Activation of the alternative complement pathway: clinical application of a new technique to measure fragment Ba.
Senaldi G, Peakman M, Alhaq A, Makinde V, TEE D, Vergani D
J Clin Pathol. 1987; 40(10):1235-9.
PMID: 3680549
PMC: 1141202.
DOI: 10.1136/jcp.40.10.1235.
Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.
Burger R, Bader A, Kirschfink M, Rother U, Schrod L, Worner I
Clin Exp Immunol. 1987; 68(3):703-11.
PMID: 3498585
PMC: 1542768.
Clinical application of new technique that measures C4d for assessment of activation of classical complement pathway.
Davies E, Nasaruddin B, Alhaq A, Senaldi G, Vergani D
J Clin Pathol. 1988; 41(2):143-7.
PMID: 3350977
PMC: 1141368.
DOI: 10.1136/jcp.41.2.143.
T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis.
Emeson E, ROBERTSON Jr A
Am J Pathol. 1988; 130(2):369-76.
PMID: 3257650
PMC: 1880529.
Anti-immunoglobulin pretreatment induces a calcium-mobilization response to the chemotactic agent N-formylmethionylleucylphenylalanine in Daudi lymphoblastoid cells.
Kalunta C, Kaptein J, Niedzin H, Scott S, Lee G, Lad P
Proc Natl Acad Sci U S A. 1988; 85(23):9204-8.
PMID: 3194420
PMC: 282707.
DOI: 10.1073/pnas.85.23.9204.
Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B.
Oppermann M, Haubitz M, Quentin E, Gotze O
Klin Wochenschr. 1988; 66(18):857-64.
PMID: 3184764
DOI: 10.1007/BF01728947.
Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones.
Arvieux J, Yssel H, Colomb M
Immunology. 1988; 65(2):229-35.
PMID: 2973431
PMC: 1384918.
Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis.
Mollison K, Mandecki W, Zuiderweg E, Fayer L, Fey T, KRAUSE R
Proc Natl Acad Sci U S A. 1989; 86(1):292-6.
PMID: 2643101
PMC: 286450.
DOI: 10.1073/pnas.86.1.292.
Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
Lambris J, Ganu V, Hirani S, MULLER-EBERHARD H
Proc Natl Acad Sci U S A. 1985; 82(12):4235-9.
PMID: 2408276
PMC: 397971.
DOI: 10.1073/pnas.82.12.4235.
Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.
Horstmann R
Infect Immun. 1992; 60(3):721-7.
PMID: 1541544
PMC: 257545.
DOI: 10.1128/iai.60.3.721-727.1992.